BTIG initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $26 price target Aardvark is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi syndrome, and ARD-201 for weight loss and weight rebound prevention, the analyst tells investors in a research note. The firm believes ARD-101’s “excellent” safety profile and “differentiated” mechanism are underappreciated by the Street. The real share upside, however, comes from ARD-201 and the opportunity to prevent weight regain from GLP-1 discontinuations, contends BTIG.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics Hosts Investor Webinar on Drug Programs
- Promising Potential of Aardvark Therapeutics: Buy Rating Based on ARD-201 and ARD-101 Developments
- Aardvark Therapeutics Showcases Obesity Research at ObesityWeek
- Aardvark Therapeutics presents data on metabolic obesity pipeline programs
- Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study